#India #Piramal Pharma #spray drying #Peptide Facility #Turbhe

Expanding the Future of Peptides at Piramal Pharma Solutions

Piramal Pharma Solutions (PPS), a renowned Contract Development and Manufacturing Organization (CDMO), has made a significant leap forward in the field of peptide development. On August 4, 2026, the company opened a state-of-the-art spray drying suite at its peptide manufacturing facility in Turbhe, India. This strategic move not only enhances PPS's manufacturing capabilities but also addresses the increasing demand for sophisticated peptide formulations across the pharmaceutical industry.

The Power of Spray Drying

The new spray drying suite is equipped to handle a range of complex formulations, focusing primarily on challenging molecules like peptides and High Potency Active Pharmaceuticals Ingredients (HPAPIs). Spray drying transforms liquid formulations into dry powders in a single-step process, which is crucial for maintaining the stability and bioavailability of peptide APIs. The technology empowers drug developers to manage sensitive compounds while achieving precise particle sizes and improved solubility, essential attributes for effective drug delivery.

Dr. Jordi Bacardit, the Global Technical Lead on Peptides at PPS, emphasizes the complexity inherent in formulating peptides due to their sensitivity to temperature and processing conditions. The introduction of the spray drying suite offers a vital solution by allowing for meticulous control over critical parameters like temperature and solvent environment, thereby ensuring that the quality and integrity of the peptide formulations are preserved during the manufacturing process.

Features of the New Facility

The advanced spray drying suite is designed as a closed-loop system, featuring its own inert gas supply and state-of-the-art safety measures. These include specialized HVAC systems, airlocked entries and exits, operator isolation areas, and a dedicated cleaning zone to ensure the safe handling of potent compounds and organic solvents that may require up to Band 5 containment. Additionally, the processing area is maintained at ISO Class 8 cleanliness standards, ensuring an optimal environment for sensitive manufacturing operations.

Capable of supporting small-volume, high-potency batches, the suite boasts a feed rate of up to 1 liter per hour. This allows spray drying of highly concentrated solutions, even those containing up to 30% water. This unique capability is particularly advantageous for biomolecule formulations and larger peptides, which often encounter challenges during development and scale-up.

Meeting the Demand for Complex Therapeutics

The expansion at the Turbhe facility underscores PPS’s commitment to being a reliable partner in the pharmaceutical sector amid the rising relevance of peptides and other complex molecules. As these components play an increasingly crucial role in modern medicine, the ability to navigate their intricacies is invaluable. The new spray drying suite places PPS at the forefront of this emerging market, reinforcing its status as a trusted provider across various therapeutic areas.

About Piramal Pharma Solutions

Piramal Pharma Solutions offers end-to-end solutions across the drug life cycle, with an extensive global network that encompasses facilities across North America, Europe, and Asia. In addition to peptide and high-potency API development, PPS provides comprehensive services from drug discovery through to clinical trial supplies and commercial supply of APIs and finished dosage forms. Their diverse service offering also includes specialized areas such as biologics, including vaccines and gene therapies, allowing them to cater to a wide array of client needs.

In summary, with the introduction of this new spray drying technology, Piramal Pharma Solutions continues to lead the way in pharmaceutical manufacturing, reinforcing its vital role in advancing healthcare by delivering high-quality and innovative therapies to patients globally.